On Jan. 26, 2018, the U.S. Centers for Disease Control and Prevention’ (CDC) Immunization Practices Advisory Committee (ACIP) recommended the Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01_B), for the prevention of herpes zoster in adults aged ≥50 years.